Insights

Innovation in Neuroimaging Qynapse offers an FDA-cleared and CE-marked AI-powered neuroimaging platform, QyScore®, that provides highly reliable and accurate MRI analysis for CNS disorders. This positions the company to target hospitals, neuroimaging centers, and pharmaceutical firms seeking advanced diagnostic solutions.

Expanding Market Presence With active participation in major international neuroimaging and radiology congresses such as the European Congress of Radiology and the French Society of Neuroradiology, Qynapse is enhancing its visibility among key medical stakeholders, creating opportunities to establish new partnerships and customer relationships.

Research and Clinical Collaborations Strategic partnerships with renowned institutions like the University of Miami Miller School of Medicine and Brigham and Women’s Hospital demonstrate a focus on advancing CNS research and clinical care, opening avenues for sales in academic and healthcare systems needing cutting-edge neuroimaging tools.

Growing Predictive Platform Qynapse's development of QyPredict® for disease trajectory forecasting offers new opportunities for pharma companies and clinical trial organizations looking to improve patient selection and trial success rates with AI-driven predictive models.

Funding and Revenue Potential With $3 million in funding and revenue estimates near the million-dollar range, Qynapse is positioned for growth, making it an attractive target for strategic investors and potential buyers interested in expanding AI-enabled neuroimaging markets.

Qynapse Tech Stack

Qynapse uses 8 technology products and services including Dataiku, Meta, GDPR, and more. Explore Qynapse's tech stack below.

  • Dataiku
    Advanced Analytics And Data Science
  • Meta
    Advertising
  • GDPR
    Certificates
  • SAP
    Customer Relationship Management
  • MySQL
    Database
  • DuckDB
    Database
  • Really Simple SSL & Security
    Security
  • Google Tag Manager
    Tag Management

Media & News

Qynapse's Email Address Formats

Qynapse uses at least 1 format(s):
Qynapse Email FormatsExamplePercentage
FLast@qynapse.comJDoe@qynapse.com
100%

Frequently Asked Questions

Where is Qynapse's headquarters located?

Minus sign iconPlus sign icon
Qynapse's main headquarters is located at 130 Rue de Lourmel Paris, Île-de-france 75015 France. The company has employees across 2 continents, including EuropeNorth America.

What is Qynapse's official website and social media links?

Minus sign iconPlus sign icon
Qynapse's official website is qynapse.com and has social profiles on LinkedInCrunchbase.

What is Qynapse's NAICS code?

Minus sign iconPlus sign icon
Qynapse's NAICS code is 3391 - Medical Equipment and Supplies Manufacturing.

How many employees does Qynapse have currently?

Minus sign iconPlus sign icon
As of April 2026, Qynapse has approximately 22 employees across 2 continents, including EuropeNorth America. Key team members include Ceo & Founder: O. C.Chief Financial Officer: L. G.Chief Product And Technical Officer: S. B.. Explore Qynapse's employee directory with LeadIQ.

What industry does Qynapse belong to?

Minus sign iconPlus sign icon
Qynapse operates in the Medical Equipment Manufacturing industry.

What technology does Qynapse use?

Minus sign iconPlus sign icon
Qynapse's tech stack includes DataikuMetaGDPRSAPMySQLDuckDBReally Simple SSL & SecurityGoogle Tag Manager.

What is Qynapse's email format?

Minus sign iconPlus sign icon
Qynapse's email format typically follows the pattern of FLast@qynapse.com. Find more Qynapse email formats with LeadIQ.

How much funding has Qynapse raised to date?

Minus sign iconPlus sign icon
As of April 2026, Qynapse has raised $3M in funding. The last funding round occurred on Jun 24, 2021 for $3M.

When was Qynapse founded?

Minus sign iconPlus sign icon
Qynapse was founded in 2015.
Qynapse logo

Qynapse

Medical Equipment ManufacturingÎle-de-france, France11-50 Employees

Qynapse is a medical device company focused on neuroimaging analysis that supports clinicians, patients, payers, and pharmaceutical researchers by providing reliable, objective measures from MRI scans. Its flagship platform, QyScore, is FDA-cleared and CE-marked and leverages proprietary artificial intelligence to enhance the accuracy and consistency of readings for central nervous system disorders, including Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease. The company also develops QyPredict, a research-use-only platform designed to model disease trajectories and potentially improve patient selection and trial design in CNS research.

Headquartered in Paris with additional operations in the United States and Canada, Qynapse collaborates with scientific and clinical partners to advance neuroimaging solutions. Its target market includes clinicians, researchers, payers, and pharma, and the company positions itself within the medical equipment manufacturing sector by delivering imaging analysis tools that aim to increase diagnostic precision and support clinical development in CNS conditions. A recent public focus includes participation in major European radiology and neuroradiology conferences, signaling ongoing engagement with the wider neuroimaging community.

Section iconCompany Overview

Headquarters
130 Rue de Lourmel Paris, Île-de-france 75015 France
NAICS Code
3391 - Medical Equipment and Supplies Manufacturing
Founded
2015
Employees
11-50

Section iconFunding & Financials

  • $3M

    Qynapse has raised a total of $3M of funding over 4 rounds. Their latest funding round was raised on Jun 24, 2021 in the amount of $3M.

  • $1M

    Qynapse's revenue is estimated to be in the range of $1M

Section iconFunding & Financials

  • $3M

    Qynapse has raised a total of $3M of funding over 4 rounds. Their latest funding round was raised on Jun 24, 2021 in the amount of $3M.

  • $1M

    Qynapse's revenue is estimated to be in the range of $1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.